Ipsen announced its second resupply of Increlex (mecasermin [rDNA origin]) injection will be available in September 2014. The first batch was available in June 2014.

RELATED: Increlex Resupply Announced for June

Increlex is a recombinant human insulin-like growth factor-1 (rhIGF-1) indicated for growth failure in children with severe IGF-1 deficiency or in those with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. The metabolic actions of IGF-1 are in part directed at stimulating the uptake of glucose, fatty acids, and amino acids so that metabolism supports growing tissues.

Increlex will be available as a multi-dose vial with a concentration of 10mg/mL (40mg/vial).

For more information call (866) 837-2422 or visit Increlex.com.